Malignant Ventricular Arrhythmic Storm Triggered by Short-coupled Premature Ventricular Contractions Arising from the Anterolateral Papillary Muscle

Peter Kabunga,1 Caroline Medi,1 Laura Yeates1 and Raymond W Sy1,3

1. Department of Cardiology, Royal Prince Alfred Hospital, New South Wales, Australia; 2. Agnes Ginges centre for Molecular Cardiology, Centenary Institute, New South Wales, Australia; 3. Sydney Medical School, University of Sydney, New South Wales, Australia.

Abstract
A case of idiopathic ventricular fibrillation (VF), triggered by ectopic beats originating from the anterolateral papillary muscle, is presented. The arrhythmia was characterised by short-coupled premature ventricular contractions (PVCs), which were resistant to isoproterenol, and ultimately treated with catheter ablation.

Keywords
Idiopathic ventricular fibrillation, papillary muscle, isoproterenol

Premature ventricular contractions (PVCs) arising from the Purkinje network are rare causes of idiopathic ventricular fibrillation (VF).1–3 Van Herendael and colleagues recently highlighted the importance of triggers from the papillary muscles (PM) and the left ventricular outflow tract in the initiation of ventricular fibrillation.4 In their study, eight of 30 patients had PM triggers which were successfully targeted with catheter ablation. Although acute success was reported in all PM-mediated ventricular tachycardia (VT)/ventricular fibrillation (VF) patients, 38% of patients had a recurrence of PVCs during long-term monitoring, perhaps due to poor catheter stability and presumed intramurality of target sites.

A range of medical therapies – including beta-blockers, amiodarone, verapamil and quinidine – have been variably described in the long-term management of idiopathic VF. In addition, isoproterenol has been acutely used in the setting of idiopathic VF storms associated with early repolarisation syndromes.5–7 However, there are few reports regarding the specific response of PM-mediated VT/VF to pharmacological therapy.

We report a case of a malignant, isoproterenol-resistant VF storm, triggered by short-coupled monomorphic PVCs originating from the anterolateral papillary muscle (APM) successfully treated with catheter ablation.

Case report
A 47-year-old woman presented to her local hospital with recurrent nocturnal seizures. Cardiac monitoring revealed non-sustained polymorphic ventricular tachycardia and ventricular fibrillation preceding seizure activity. Over the ensuing 24 hours, she received 10 shocks, despite a sequential trial of pharmacological therapy with intravenous (IV) amiodarone (300 mg bolus plus 900 mg continuous infusion), 40 mmol of magnesium sulphate (MgSO4), 40 mmol of potassium chloride (KCl) and boluses of IV metoprolol. Isoproterenol was then administered at the peripheral hospital as she continued to get multiple PVCs and non-sustained VT and the patient was transferred to our centre for further evaluation.

She had been previously treated with carbamazepine and valproate for 10 years, with the presumed diagnosis of epilepsy. Notably, the patient’s symptoms pre-dated the prescription of anti-epileptic medications. There was also a family history of premature sudden cardiac death (Figure 1).

Baseline investigations including electrolytes, trans-thoracic echocardiogram (TTE), and electrocardiogram (ECG) (including QT interval) during sinus rhythm were normal. The QRS complexes in leads V1–V3 remained normal in all ECGs, and there was no J-point elevation observed before or after episodes of arrhythmia (Figure 2). Episodes of sustained ventricular arrhythmia appeared to be consistently triggered by monomorphic PVCs with a short coupling interval (240 ms) (Figure 3). Interestingly, we did not observe a critical difference in the coupling intervals between isolated PVCs and those PVCs initiating torsades de pointes/VF (Figures 2 and 3). Coronary angiography, cardiac magnetic resonance, flecainide challenge and signal averaged ECG, were normal.
Case Report  Electrophysiology

Figure 1: Family pedigree and baseline electrocardiogram

![Family pedigree and baseline electrocardiogram](image)

Figure 2: Short-coupled premature ventricular contraction initiating ventricular fibrillation

![Short-coupled premature ventricular contraction initiating ventricular fibrillation](image)

Even though there was no definite evidence of early repolarisation syndrome, isoproterenol (2 mcg/min) was empirically continued in an attempt to suppress VF. However, isoproterenol was associated with an abrupt increase in the frequency of PVCs and non-sustained ventricular tachycardia (NSVT) and it was ceased. Intravenous esmolol (2.5 g infusion) suppressed the NSVT but isolated breakthrough PVCs remained. An electrophysiology (EP) study was performed due to persistence of short-coupled PVCs (Figure 2).

The EP study was performed with minimal sedation. Baseline EP was unremarkable with normal baseline intervals (QTc, AH, HV). Clinical PVCs were infrequently observed at baseline. Ventricular effective refractory period was 230 ms. Ventricular arrhythmias were not inducible with burst pacing or programmed electrical stimulation (PES) with up to four extra-stimuli delivered from the right ventricular apex to refractoriness using two drive cycles (600 ms, 400 ms). Electro-anatomical mapping (Carto-3, Biosense-Webster) of the left ventricle was performed using a combined retro-aortic and transseptal approach. Unipolar and bipolar voltage maps of the left ventricle were normal. Activation mapping was not feasible due to paucity of PVCs at baseline and with isoproterenol (up to 5 mcg/min). There were subtle differences in the morphology of the spontaneous PVCs at the time of the EP study when compared to the PVCs previously captured on the ward, but this was probably related to differences in lead positioning. The PVC morphology was suggestive of an origin in the mid-antero-lateral LV and detailed pace-mapping was performed in this region. Subtle differences in the morphology of the QRS complex were observed when pacing at different sites along the antero-lateral papillary muscle (e.g. base versus apex, anterior versus posterior). The best pace-map appeared to be reproducible when pacing at low output within a relatively small area of the papillary muscle. However, this observation was limited by catheter movement related to cardio-respiratory motion, and the spatial resolution of the electro-anatomical mapping system and real-time echocardiography (Figure 4 and video). TTE was used instead of intra-cardiac echocardiography (ICE) in this case because the latter was not immediately available given the emergent nature of the procedure. There appeared to be latency (~20 ms) between the pacing stimulus and the onset of the surface QRS. At the onset of radiofrequency (RF) applications (irrigated 35 Watts, 45°C), PVC automaticity matching the clinical template was seen (Figure 4).

Following this, no further spontaneous PVCs or ventricular arrhythmias were observed. In addition, PES using up to four extra-stimuli as well as burst pacing delivered from the right ventricular apex and the left ventricle did not induce any ventricular arrhythmias either from the target or remote sites. No PVCs were seen during extended in-hospital telemetry over the ensuing seven days. There was also no evidence of inducible ventricular ectopy on adrenaline challenge or exercise testing. A single chamber implantable cardioverter-defibrillator was implanted and the patient remains arrhythmia free with a very low PVC count, off medications at 17 months follow-up.

Discussion

The diagnosis in this case was a variant of short-coupled idiopathic ventricular fibrillation, triggered by PVCs originating from the papillary muscle. The case highlights the malignant nature of this arrhythmia, and the challenges in its management including the role of ablation.

Transmural dispersion of repolarisation is thought to predispose the ventricular myocardium to phase two re-entry-mediated VF following excitation by short-coupled PVCs. Isoproterenol reverses this repolarisation abnormality by homogenising transmural and epicardial electrical gradients, and is effective in terminating idiopathic VF (VF) associated with early repolarisation (ER). Our patient had no obvious ER and she experienced an increase in PVC and NSVT burden with isoproterenol and improvement with esmolol, perhaps indicating that phase two re-entry was not the underlying mechanism of VF initiation. Because of a low baseline blood pressure, she was prescribed a small dose of metoprolol (25 mg twice daily), which she voluntarily ceased during follow-up. Improvement with beta-blockers and an increase in short coupled PVCs with isoproterenol is more typical for cyclic AMP-mediated triggered activity seen in the rare, malignant forms of outflow tract ventricular arrhythmias. Beta-blockers are usually effective because they inhibit adenylate cyclase, which leads to a decrease
Malignant Ventricular Arrhythmic Storm Triggered by Short-coupled Premature Ventricular Contractions

Leenhardt et al. have previously described a short-coupled variant of idiopathic VF presenting with torsade de pointes. In their study of 14 patients with apparently normal baseline ECGs, ventricular arrhythmia was induced with PES in only one patient. Response to isoproterenol was variable, with suppression of PVCs in three patients, no effect in six patients, and an increase in two patients. They reported the efficacy of verapamil but not beta-blockers, in some patients. However, verapamil did not universally protect against sudden death, highlighting the need for implantable cardioverter defibrillator (ICD) therapy. Kondo et al. have also recently described a 19-year-old patient with short-coupled PVCs precipitating VF. Interestingly, their patient had infralateral ER but isoproterenol infusion increased PVCs, while verapamil and propranolol infusion suppressed them. Clinical PVCs were not elicited with PES and catheter ablation at a site in the right ventricular Purkinje system successfully terminated the PVCs. Isoproterenol-resistant PVCs triggering recurrent VF has also been described in a patient with Brugada syndrome (BrS), suggesting a rare subset of patients with BrS/IVF exists with non-phase two-mediated re-entry as a mechanism for Brugada syndrome (BrS). It remains speculative whether sensitivity to beta-adrenergic after-depolarisations typical for triggered arrhythmias such as outflow tract VT. It remains speculative whether sensitivity to beta-adrenergic after-depolarisations typical for triggered arrhythmias such as outflow tract VT. It remains speculative whether sensitivity to beta-adrenergic after-depolarisations typical for triggered arrhythmias such as outflow tract VT. It remains speculative whether sensitivity to beta-adrenergic after-depolarisations typical for triggered arrhythmias such as outflow tract VT. It remains speculative whether sensitivity to beta-adrenergic after-depolarisations typical for triggered arrhythmias such as outflow tract VT. It remains speculative whether sensitivity to beta-adrenergic after-depolarisations typical for triggered arrhythmias such as outflow tract VT. It remains speculative whether sensitivity to beta-adrenergic after-depolarisations typical for triggered arrhythmias such as outflow tract VT. It remains speculative whether sensitivity to beta-adrenergic after-depolarisations typical for triggered arrhythmias such as outflow tract VT. It remains speculative whether sensitivity to beta-adrenergic after-depolarisations typical for triggered arrhythmias such as outflow tract VT. It remains speculative whether sensitivity to beta-adrenergic after-depolarisations typical for triggered arrhythmias such as outflow tract VT. It remains speculative whether sensitivity to beta-adrenergic after-depolarisations typical for triggered arrhythmias such as outflow tract VT. It remains speculative whether sensitivity to beta-adrenergic after-depolarisations typical for triggered arrhythmias such as outflow tract VT. It remains speculative whether sensitivity to beta-adrenergic after-depolarisations typical for triggered arrhythmias such as outflow tract VT. It remains speculative whether sensitivity to beta-adrenergic after-depolarisations typical for triggered arrhythmias such as outflow tract VT. It remains speculative whether sensitivity to beta-adrenergic after-depolarisations typical for triggered arrhythmias such as outflow tract VT. It remains speculative whether sensitivity to beta-adrenergic after-depolarisations typical for triggered arrhythmias such as outflow tract VT. It remains speculative whether sensitivity to beta-adrenergic after-depolarisations typical for triggered arrhythmias such as outflow tract VT. It remains speculative whether sensitivity to beta-adrenergic after-depolarisations typical for triggered arrhythmias such as outflow tract VT. It remains speculative whether sensitivity to beta-adrenergic after-depolarisations typical for triggered arrhythmias such as outflow tract VT. It remains speculative whether sensitivity to beta-adrenergic after-depolarisations typical for triggered arrhythmias such as outflow tract VT. It remains speculative whether sensitivity to beta-adrenergic after-depolarisations typical for triggered arrhythmias such as outflow tract VT. It remains speculative whether sensitivity to beta-adrenergic after-depolarisations typical for triggered arrhythmias such as outflow tract VT. It remains speculative whether sensitivity to beta-adrenergic after-depolarisations typical for triggered arrhythmias such as outflow tract VT. It remains speculate...